![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Hadassah Medical Organization |
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00162383 |
The ability to metabolize drugs varies greatly among individuals. Major fraction of this variability lies in genetic polymorphisms of genes encoding for enzymes responsible for both phase I and phase II reactions.
The purpose of this study ws to evaluate the phenotypic activity and the frequency of genetic polymorphisms in different phase II and phase I enzymes among various populations residing in Israel.
Condition | Intervention |
Healthy Volunteers |
Drug: Debrisoquine Drug: Mephenytoin Drug: Dapsone Drug: Caffeine |
MedlinePlus related topics: | Caffeine |
ChemIDplus related topics: | Dapsone 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione Caffeine citrate Debrisoquin Debrisoquin sulfate Mephenytoin |
Study Type: | Interventional |
Study Design: | Other, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Phenotypic and Genotypic Evaluation of Cytochrome P450 Isoforms in Populations of Different Ethnic Composition |
Ages Eligible for Study: | 20 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | yc19551-HMO-CTIL |
First Received: | September 11, 2005 |
Last Updated: | March 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00162383 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
|
|
|
![]() |